More than 900 Biologics in Development
America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report.
America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a
released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
The report includes biologics in human clinical trials or under review by FDA such as 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma; 134 vaccines for infectious diseases; 71 medicines for autoimmune diseases including lupus, multiple sclerosis, and rheumatoid arthritis; and 58 treatments for cardiovascular disease.
Among the biologic medicines in development are a genetically-modified virus-based vaccine to treat melanoma; a monoclonal antibody for the treatment of asthma; an antisense therapy for the treatment of leukemia; a recombinant fusion protein to treat Type II diabetes.
The report lists the product name, sponsor, product category, indication, and development phase.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
